Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Tredaptive (Niacin/Laropiprant) in Dyslipidemia
NCT00664287Phase 3Withdrawn
- Sponsor
- Merck & Co.
- Start
- Sep 2008
- Primary completion
- Nov 2009
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of laropiprant in dyslipidemia, sponsored by Merck & Co.. Planned start Sep 2008; status: withdrawn.
02
Drugs
laropiprant
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT00664287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00664287.